Literature DB >> 21912433

PPI therapy: PPI plus aspirin for secondary cardiovascular disease prevention.

Siew C Ng, Francis K L Chan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21912433     DOI： 10.1038/nrgastro.2011.164

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

Authors:  Deepak L Bhatt; James Scheiman; Neena S Abraham; Elliott M Antman; Francis K L Chan; Curt D Furberg; David A Johnson; Kenneth W Mahaffey; Eamonn M Quigley
Journal:  Circulation       Date:  2008-10-03       Impact factor: 29.690

2.  Does PPI therapy predispose to Clostridium difficile infection?

Authors:  Chaitanya Pant; Phillip Madonia; Anil Minocha
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

3.  Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.

Authors:  S D Saini; A M Fendrick; J M Scheiman
Journal:  Aliment Pharmacol Ther       Date:  2011-05-25       Impact factor: 8.171

4.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Authors:  Francis K L Chan; Jessica Y L Ching; Lawrence C T Hung; Vincent W S Wong; Vincent K S Leung; Nelson N S Kung; Aric J Hui; Justin C Y Wu; Wai K Leung; Vivian W Y Lee; Kenneth K C Lee; Yuk T Lee; James Y W Lau; Ka F To; Henry L Y Chan; S C Sydney Chung; Joseph J Y Sung
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Authors:  Stephanie R Earnshaw; James Scheiman; A Mark Fendrick; Cheryl McDade; Michael Pignone
Journal:  Arch Intern Med       Date:  2011-02-14

6.  Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.

Authors:  Joseph J Y Sung; James Y W Lau; Jessica Y L Ching; Justin C Y Wu; Yuk T Lee; Philip W Y Chiu; Vincent K S Leung; Vincent W S Wong; Francis K L Chan
Journal:  Ann Intern Med       Date:  2009-11-30       Impact factor: 25.391

7.  Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.

Authors:  Sameer D Saini; Philip Schoenfeld; A Mark Fendrick; James Scheiman
Journal:  Arch Intern Med       Date:  2008-08-11

8.  Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome.

Authors:  Chiara Melloni; Karen P Alexander; Fang-Shu Ou; Nancy M Allen LaPointe; Matthew T Roe; L Kristin Newby; Khaula Baloch; P Michael Ho; John S Rumsfeld; Eric D Peterson
Journal:  Am J Cardiol       Date:  2009-06-03       Impact factor: 2.778

9.  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

Authors:  Kam Chuen Lai; Shiu Kum Lam; Kent Man Chu; Benjamin C Y Wong; Wai Mo Hui; Wayne H C Hu; George K K Lau; Wai Man Wong; Man Fung Yuen; Annie O O Chan; Ching Lung Lai; John Wong
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.